IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.

ABSTRACT:

Background

Systemic administration of IL-12p70 has demonstrated clinical activity in cancer patients, but dose-limiting toxicities have hindered its incorporation in vaccine formulations. Here, we report on the immunological and clinical outcomes upon vaccination with CD40L/IFN-γ-matured, IL-12p70-producing DCs.

Methods

7 HLA-A*0201+ newly diagnosed stage IV melanoma patients were immunized against the gp100 melanoma antigen using autologous peptide-pulsed, CD40L/IFN-γ-matured DCs. PBMCs were taken weekly for immune monitoring by tetramer analysis and functional assays. CT imaging was performed at baseline, week 9, and week 18 for clinical assessment using RECIST.

Results

6 of 7 treated patients developed sustained T cell immunity to all 3 melanoma gp100 antigen-deriv

SUBMITTER: Carreno BM 

PROVIDER: S-EPMC3726168 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature